<DOC>
	<DOCNO>NCT01110187</DOCNO>
	<brief_summary>Trial determine seizure prophylaxis IV LCM NSICU patient experience mental status change due severe traumatic brain injury ( sTBI ) result improve short- long-term outcome well immediate adverse effect compare current standard care anticonvulsant ( IV fPHT ) least effective IV fPHT prevent clinical sub-clinical seizure activity .</brief_summary>
	<brief_title>A Pilot Study NSICU Assessment Seizure Prophylaxis With Lacosamide</brief_title>
	<detailed_description>The goal compare IV LCM IV fPHT seizure prophylaxis neuro-critical care set term follow outcome measure : 1 . The short- long-term incidence adverse event related anticonvulsant medication 2 . The frequency clinically-evident sub-clinical seizure , demonstrate continuous EEG monitoring first three day clinical assessment 6 month initial admission . 3 . Intermediate long-term outcome measure standard outcome measure include Extended Glasgow Outcome Scale , Disability Rating Scale , Resource Utilization Questionnaire</detailed_description>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Fosphenytoin</mesh_term>
	<criteria>Subject traumatic brain injury admit hospital le 24 hour prior randomization GCS score 38 ( inclusive ) GCS motor score 5 less abnormal admission CT scan show intracranial pathology Hemodynamically stable systolic BP &gt; 90 mmHg At least one reactive pupil Age least 18 year Signed informed consent HIPAA authorization research form Patients exclude race , gender , educational status occupation No venous access Spinal cord injury History CT confirmation previous brain injury brain tumor , cerebral infarct , spontaneous intracerebral hemorrhage Hemodynamically unstable Suspected anoxic event Other peripheral trauma likely result liver failure Age le 18 year age Known hypersensitivity anticonvulsant Any treatment , condition , injury contraindicates treatment Lacosamide ( LCM ) fosphenytoin ( fPHT ) Inability obtain sign informed consent HIPAA authorization research</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Fosphenytoin</keyword>
	<keyword>traumatic brain injury</keyword>
	<keyword>Glasgow coma scale</keyword>
	<keyword>Disability Rating Scale</keyword>
	<keyword>Resource Utilization Questionnaire</keyword>
	<keyword>Continuous EEG</keyword>
	<keyword>seizure</keyword>
</DOC>